$EYPT
EyePoint Pharmaceuticals, Inc.

2012 Q4 Form 10-Q Financial Statement

#000119312512462802 Filed on November 09, 2012

View on sec.gov

Income Statement

Concept 2012 Q4 2012 Q3 2011 Q3
Revenue $585.0K $553.0K $1.659M
YoY Change -7.14% -66.67% 248.53%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.660M $1.620M $2.060M
YoY Change 14.48% -21.36% -5.07%
% of Gross Profit
Research & Development $1.575M $1.523M $2.129M
YoY Change -20.93% -28.46% 22.36%
% of Gross Profit
Depreciation & Amortization $250.0K $55.00K $24.00K
YoY Change -71.26% 129.17% -97.07%
% of Gross Profit
Operating Expenses $3.233M $3.143M $4.190M
YoY Change -82.31% -24.99% 7.16%
Operating Profit -$2.648M -$2.590M -$2.531M
YoY Change -84.99% 2.33% -26.32%
Interest Expense $0.00 $10.00K $50.00K
YoY Change -100.0% -80.0% -85.29%
% of Operating Profit
Other Income/Expense, Net $3.000K $6.000K $49.00K
YoY Change -97.84% -87.76% -590.0%
Pretax Income -$2.645M -$2.584M -$2.482M
YoY Change -84.89% 4.11% -19.94%
Income Tax -$37.00K -$33.00K $55.00K
% Of Pretax Income
Net Earnings -$2.608M -$2.551M -$2.427M
YoY Change -85.06% 5.11% -21.91%
Net Earnings / Revenue -445.81% -461.3% -146.29%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.120M -$1.143M -$1.168M
COMMON SHARES
Basic Shares Outstanding 23.30M shares 23.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q4 2012 Q3 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.70M $17.60M $21.30M
YoY Change -16.04% -17.37% 39.22%
Cash & Equivalents $9.409M $8.388M $9.811M
Short-Term Investments $6.300M $9.300M $11.50M
Other Short-Term Assets $100.0K $300.0K $300.0K
YoY Change -50.0% 0.0% 50.0%
Inventory
Prepaid Expenses
Receivables $900.0K $900.0K $700.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $16.81M $18.90M $22.30M
YoY Change -15.53% -15.25% 30.41%
LONG-TERM ASSETS
Property, Plant & Equipment $277.0K $289.0K $400.0K
YoY Change -30.75% -27.75% 300.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $4.232M $4.439M $20.80M
YoY Change -15.36% -78.66% -12.97%
TOTAL ASSETS
Total Short-Term Assets $16.81M $18.90M $22.30M
Total Long-Term Assets $4.232M $4.439M $20.80M
Total Assets $21.04M $23.34M $43.10M
YoY Change -15.49% -45.85% 5.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $215.0K $266.0K $500.0K
YoY Change -28.33% -46.8% 25.0%
Accrued Expenses $1.084M $801.0K $800.0K
YoY Change 54.86% 0.13% -11.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.083M $3.462M $4.000M
YoY Change -19.88% -13.45% 73.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.100M $3.700M $3.900M
YoY Change 13.33% -5.13% -46.58%
Total Long-Term Liabilities $5.100M $3.700M $3.900M
YoY Change 13.33% -5.13% -46.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.083M $3.462M $4.000M
Total Long-Term Liabilities $5.100M $3.700M $3.900M
Total Liabilities $7.232M $7.176M $7.900M
YoY Change 0.44% -9.16% -20.2%
SHAREHOLDERS EQUITY
Retained Earnings -$256.9M -$254.3M
YoY Change
Common Stock $23.00K $23.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.81M $16.16M $35.20M
YoY Change
Total Liabilities & Shareholders Equity $21.04M $23.34M $43.10M
YoY Change -15.49% -45.85% 5.12%

Cashflow Statement

Concept 2012 Q4 2012 Q3 2011 Q3
OPERATING ACTIVITIES
Net Income -$2.608M -$2.551M -$2.427M
YoY Change -85.06% 5.11% -21.91%
Depreciation, Depletion And Amortization $250.0K $55.00K $24.00K
YoY Change -71.26% 129.17% -97.07%
Cash From Operating Activities -$1.780M -$1.621M -$2.660M
YoY Change -24.58% -39.06% 19.82%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K $4.000K $221.0K
YoY Change -75.0% -98.19% -2310.0%
Acquisitions
YoY Change
Other Investing Activities $2.900M $650.0K -$330.0K
YoY Change 158.93% -296.97% -89.59%
Cash From Investing Activities $2.870M $647.0K -$552.0K
YoY Change 198.96% -217.21% -82.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.735M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -70.00K 4.735M 114.0K
YoY Change 4053.51%
NET CHANGE
Cash From Operating Activities -1.780M -1.621M -2.660M
Cash From Investing Activities 2.870M 647.0K -552.0K
Cash From Financing Activities -70.00K 4.735M 114.0K
Net Change In Cash 1.020M 3.761M -3.098M
YoY Change -172.86% -221.4% -42.63%
FREE CASH FLOW
Cash From Operating Activities -$1.780M -$1.621M -$2.660M
Capital Expenditures -$40.00K $4.000K $221.0K
Free Cash Flow -$1.740M -$1.625M -$2.881M
YoY Change -20.91% -43.6% 30.36%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23297011 shares
CY2012Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
2.15
CY2012Q3 psdv Common Stock Warrant Exercise Price Per Share
CommonStockWarrantExercisePricePerShare
2.50
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9811000
CY2011Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2011Q3 psdv Unrecognized Tax Benefit
UnrecognizedTaxBenefit
0
CY2012Q3 us-gaap Other Assets
OtherAssets
72000
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2012Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1009000
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3462000
CY2012Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
316000
CY2012Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2395000
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-254309000
CY2012Q3 us-gaap Assets
Assets
23339000
CY2012Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
16445000
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8388000
CY2012Q3 us-gaap Deferred Revenue
DeferredRevenue
5800000
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23339000
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23297011 shares
CY2012Q3 us-gaap Common Stock Value
CommonStockValue
23000
CY2012Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
9258000
CY2012Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
938000
CY2012Q3 us-gaap Liabilities
Liabilities
7176000
CY2012Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
801000
CY2012Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
289000
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23297011 shares
CY2012Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
9258000
CY2012Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3714000
CY2012Q3 us-gaap Assets Current
AssetsCurrent
18900000
CY2012Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
269440000
CY2012Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1300000
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q3 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
9258000
CY2012Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
16163000
CY2012Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4078000
CY2012Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
266000
CY2012Q3 psdv Unrecognized Tax Benefit
UnrecognizedTaxBenefit
0
CY2012Q3 psdv Finite Lived Intangible Assets Remaining Useful Life
FiniteLivedIntangibleAssetsRemainingUsefulLife
5.25 Y
CY2012Q2 us-gaap Liabilities
Liabilities
6961000
CY2012Q3 psdv Weighted Average Maturity
WeightedAverageMaturity
3.2 M
CY2012Q3 psdv Cash Equivalents Fair Value Disclosure
CashEquivalentsFairValueDisclosure
7187000
CY2012Q3 psdv Cash And Cash Equivalents And Marketable Securities Fair Value
CashAndCashEquivalentsAndMarketableSecuritiesFairValue
17600000
CY2012Q3 psdv Estimated Annual Amortization Of Intangible Assets
EstimatedAnnualAmortizationOfIntangibleAssets
780000
CY2012Q3 psdv Warrants Outstanding Weighted Average Remaining Contract Life
WarrantsOutstandingWeightedAverageRemainingContractLife
P4Y1M6D
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12912000
CY2012Q2 us-gaap Other Assets
OtherAssets
77000
CY2012Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2012Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
942000
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3178000
CY2012Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
421000
CY2012Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2176000
CY2012Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-251758000
CY2012Q2 us-gaap Assets
Assets
20597000
CY2012Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
14238000
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4625000
CY2012Q2 us-gaap Deferred Revenue
DeferredRevenue
6000000
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20597000
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20802592 shares
CY2012Q2 us-gaap Common Stock Value
CommonStockValue
21000
CY2012Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
9954000
CY2012Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
967000
CY2012Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
608000
CY2012Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
335000
CY2012Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20802592 shares
CY2012Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
9946000
CY2012Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3783000
CY2012Q2 us-gaap Assets Current
AssetsCurrent
15959000
CY2012Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
264431000
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
9946000
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
13636000
CY2012Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4226000
CY2012Q2 us-gaap Available For Sale Securities Gross Unrealized Gain Loss
AvailableForSaleSecuritiesGrossUnrealizedGainLoss
-8000
CY2012Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
394000
CY2012Q2 psdv Cash Equivalents Fair Value Disclosure
CashEquivalentsFairValueDisclosure
4292000
CY2011Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-365000
CY2011Q3 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-13000
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
-2427000
CY2011Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
49000
CY2011Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2061000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
CY2012Q3 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
694000
CY2012Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2494419 shares
CY2012Q3 psdv Term Of Warrants Issued
TermOfWarrantsIssued
5 Y
CY2012Q3 psdv Warrants Granted To Purchase Common Stock
WarrantsGrantedToPurchaseCommonStock
623605 shares
CY2012Q3 psdv Percentage Of Shares Of Common Stock Issued Under Terms Of Warrant Transactions
PercentageOfSharesOfCommonStockIssuedUnderTermsOfWarrantTransactions
0.25 pure
CY2012Q3 psdv Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
5400000
CY2011Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2011Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
114000
CY2011Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2011Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-552000
CY2011Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000
CY2011Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2129000
CY2011Q3 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1430000
CY2011Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-363000
CY2011Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20757000 shares
CY2011Q3 us-gaap Share Based Compensation
ShareBasedCompensation
477000
CY2011Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3101000
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2531000
CY2011Q3 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-373000
CY2011Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
114000
CY2011Q3 us-gaap Royalty Revenue
RoyaltyRevenue
198000
CY2011Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2792000
CY2011Q3 us-gaap Operating Expenses
OperatingExpenses
4190000
CY2011Q3 us-gaap Revenues
Revenues
1659000
CY2011Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
85000
CY2011Q3 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-206000
CY2011Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
55000
CY2011Q3 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-3000
CY2011Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
42000
CY2011Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1461000
CY2011Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
221000
CY2011Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
833000
CY2011Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-2000
CY2011Q3 us-gaap Depreciation
Depreciation
24000
CY2011Q3 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
3731000
CY2011Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
477000
CY2011Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2482000
CY2011Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8518853 shares
CY2011Q3 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3400000
CY2011Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2660000
CY2011Q3 psdv Noncash Or Part Noncash Unpaid Property Plant Equipment And Other Assets
NoncashOrPartNoncashUnpaidPropertyPlantEquipmentAndOtherAssets
88000
CY2011Q4 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
14800000
CY2012Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2012Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2012Q3 dei Document Type
DocumentType
10-Q
CY2012Q3 dei Document Period End Date
DocumentPeriodEndDate
2012-09-30
CY2012Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001314102
CY2012Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2012Q3 dei Trading Symbol
TradingSymbol
PSDV
CY2012Q3 dei Entity Registrant Name
EntityRegistrantName
PSIVIDA CORP.
CY2012Q3 dei Amendment Flag
AmendmentFlag
false
CY2012Q3 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2012Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
647000
CY2012Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
7000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
307760 shares
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1523000
CY2012Q3 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
150000
CY2012Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
59000
CY2012Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
67000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22294000 shares
CY2012Q3 us-gaap Share Based Compensation
ShareBasedCompensation
343000
CY2012Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3763000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2590000
CY2012Q3 us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-2000
CY2012Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
343000
CY2012Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
67000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-2551000
CY2012Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6000
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1620000
CY2012Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4735000
CY2012Q3 us-gaap Royalty Revenue
RoyaltyRevenue
384000
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2484000
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
3143000
CY2012Q3 us-gaap Revenues
Revenues
553000
CY2012Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
44000
CY2012Q3 us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-147000
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
33000
CY2012Q3 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
2000
CY2012Q3 us-gaap Depreciation
Depreciation
55000
CY2012Q3 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
2799000
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
343000
CY2012Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4668000
CY2012Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
CY2012Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
193000
CY2012Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
8000
CY2012Q3 us-gaap License And Services Revenue
LicenseAndServicesRevenue
169000
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2584000
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4537220 shares
CY2012Q3 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3450000
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.65
CY2012Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4735000
CY2012Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1621000
CY2012Q3 psdv Share Based Compensation By Share Based Payment Award Options Granted Contractual Life
ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
P10Y
CY2012Q3 psdv Milestone Payment Due Upon Approval By Fda
MilestonePaymentDueUponApprovalByFda
25000000
CY2012Q3 psdv Number Of Options Vested During Period
NumberOfOptionsVestedDuringPeriod
451826 shares
CY2012Q3 psdv Equity Financing
EquityFinancing
40000000
CY2012Q3 psdv Period Of Performance Obligations Under License Agreement
PeriodOfPerformanceObligationsUnderLicenseAgreement
P17Y

Files In Submission

Name View Source Status
0001193125-12-462802-index-headers.html Edgar Link pending
0001193125-12-462802-index.html Edgar Link pending
0001193125-12-462802.txt Edgar Link pending
0001193125-12-462802-xbrl.zip Edgar Link pending
d423330d10q.htm Edgar Link pending
d423330dex311.htm Edgar Link pending
d423330dex312.htm Edgar Link pending
d423330dex321.htm Edgar Link pending
d423330dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
psdv-20120930.xml Edgar Link completed
psdv-20120930.xsd Edgar Link pending
psdv-20120930_cal.xml Edgar Link unprocessable
psdv-20120930_def.xml Edgar Link unprocessable
psdv-20120930_lab.xml Edgar Link unprocessable
psdv-20120930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending